Federal Judge Pauses Louisiana's Challenge to FDA Abortion Pill Rule

The state's lawsuit seeking to limit access to mifepristone is on hold while the FDA conducts a review of the drug's safety.

Apr. 8, 2026 at 7:50am

Got story updates? Submit your updates here. ›

A dimly lit, cinematic painting of an empty courtroom with a single judge's gavel resting on the bench, bathed in warm, diagonal sunlight and deep shadows, conveying a sense of contemplation and the weight of the legal decision at hand.The quiet, contemplative setting of a federal courtroom reflects the high-stakes legal battle over access to abortion medication.Lafayette Today

A federal judge in Louisiana has put a hold on the state's lawsuit challenging a 2023 FDA rule that allows the abortion pill mifepristone to be dispensed through the mail. The judge said the state's case should not proceed until the FDA completes its review of the drug's safety, which has reportedly been delayed until after the November midterm elections.

Why it matters

This decision is the latest development in the ongoing legal battle over access to abortion medication in the United States. The FDA's review of mifepristone, which is used in 60% of U.S. abortions, could have significant implications for reproductive rights across the country.

The details

U.S. District Judge David Joseph in Lafayette, Louisiana, ruled that the Republican-led state's challenge to the 2023 FDA rule should be paused while the agency conducts its review of mifepristone's safety. The judge said the state could renew its bid to block the rule once the case resumes, and that he would likely grant it. However, the judge noted that the New Orleans-based 5th U.S. Circuit Court of Appeals had already ruled three years ago that previous FDA rules easing access to mifepristone were unlawful, though the Supreme Court later said the plaintiffs in that case lacked legal standing.

  • The FDA launched a review of mifepristone, which it first approved in 2000, last year.
  • The FDA's review of mifepristone has reportedly been delayed until after the November 2026 midterm elections.

The players

U.S. District Judge David Joseph

A Trump appointee who presided over the case in Lafayette, Louisiana.

Louisiana Attorney General Liz Murrill

A Republican who said her office would appeal the judge's decision and ask the 5th Circuit to block the 2023 FDA rule.

FDA

The U.S. Food and Drug Administration, which launched a review of mifepristone last year and is expected to decide whether to repeal a 2023 rule allowing the abortion pill to be dispensed through the mail.

Got photos? Submit your photos here. ›

What they’re saying

“At this juncture, it is the completion of FDA's promised good faith, ​evidence-based, and expeditious review [and] not 'government by lawsuit' that this Court finds to be in the public interest.”

— U.S. District Judge David Joseph

What’s next

The Louisiana Attorney General's office has said it will appeal the judge's decision and ask the 5th Circuit Court of Appeals to block the 2023 FDA rule allowing mifepristone to be dispensed through the mail. The outcome of the FDA's review of the abortion pill's safety, which has been delayed until after the November midterm elections, will also be a key next step in this ongoing legal battle.

The takeaway

This case highlights the complex and politically charged legal landscape surrounding access to abortion medication in the United States. The judge's decision to pause Louisiana's challenge underscores the importance of the FDA's review process, even as reproductive rights advocates express concerns about potential further restrictions on mifepristone.